Story thread · 7 reports / 5 sources
Merck plans trial of sac-TMT combo with Keytruda in lung cancer
endpts.com · 7d
How the coverage leans
Across 5 sources · syndicated copies counted once
Merck provided some of the clearest direction yet regarding its ambitions in oncology to improve on its blockbuster immunotherapy Keytruda. The company plans to conduct a trial testing its experimental antibody-drug conjugate sac-TMT in combination ...
First report: Merck Lifts 2026 Sales Forecast on Strength of Newer Drugs — bloomberg.com, 7d
The coverage
- Caterpillar lifts 2026 sales growth forecast as AI buildout powers on
channelnewsasia.com · 7d
- Merck lifts sales forecast as newer drugs gain momentum
seekingalpha.com · 7d
The conversation · 0
Sign in to join the conversation.
No comments yet — start the thread.